tiprankstipranks
Amplia Therapeutics Ltd. (INNMF)
OTHER OTC:INNMF
Holding INNMF?
Track your performance easily

Amplia Therapeutics Ltd. (INNMF) Stock Price & Analysis

15 Followers

INNMF Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

4.33%95.67%
― Other Institutional Investors
95.67% Public Companies and
Individual Investors

INNMF FAQ

What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest stock price was $0.03 and its highest was $0.15 in the past 12 months.
    What is Amplia Therapeutics Ltd.’s market cap?
    Amplia Therapeutics Ltd.’s market cap is $20.90M.
      When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
      Amplia Therapeutics Ltd.’s upcoming earnings report date is Jun 02, 2025 which is in 134 days.
        How were Amplia Therapeutics Ltd.’s earnings last quarter?
        Currently, no data Available
        Is Amplia Therapeutics Ltd. overvalued?
        According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Amplia Therapeutics Ltd. pay dividends?
          Amplia Therapeutics Ltd. does not currently pay dividends.
          What is Amplia Therapeutics Ltd.’s EPS estimate?
          Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Amplia Therapeutics Ltd. have?
          Amplia Therapeutics Ltd. has 387,952,670 shares outstanding.
            What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
            Currently, no hedge funds are holding shares in INNMF
            ---

            Company Description

            Amplia Therapeutics Ltd.

            Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Race Oncology Ltd.
            Patrys Limited
            Cynata Therapeutics Limited
            Proteomics International Laboratories Ltd.
            Immutep Ltd
            Popular Stocks
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis